A team from Washington State University has crafted a new technique for the delivery of drugs and other therapies into the cells at the nanoscale level without rooting to any toxic effects that may have hindered other such research. The researchers believe that this currents study may someday lead to developing a potentially effective diagnostics and therapies for conditions like cancer or other diseases.
According to the lead researchers, Yuehe Lin and Chunlong Chen, plus the rest of the team, they have worked endlessly on creating this positive therapeutic gene model that can be delivered into the tumor cells using biologically stimulated materials at the nanoscale level. The nanomaterials are designed such that it can carry the therapeutic genes to the exact target inside the cells for the cure of diseases like cancer. However, the major drawback here is that the nanomaterials are considered to less efficient in delivering medicines as well as toxic in some cases. Thus, the researchers have worked on reducing the toxicity level. The team has designed the particle in the shape of a flower with 150 nanometers size using peptoids sheets that are exact copies of the natural peptides forming proteins. The use of peptoids is knowledgeable as it is intricate to synthesize and also compatibility with biological systems plus similarity with natural biological materials.
The peptoid nanoflowers will also have fluorescent probes added in which helps make tracing easier within the cell and the use of the element fluorine will help the nanoflower pass entrapping cellular spaces without any further impact on the drug delivery. The flower-like structure comprised of therapeutic genes could pass the cellular traps and reach the specific target in the interiors of the cells for drug release. The toxicity level was observed to highly low in the model drug molecules. This new delivery method opens up a new door for nanocargoes development as well as targeted gene therapies. The new technology has already been sent for patent approval. Researchers affiliated from the UNIST have developed a new targeted drug delivery technology that can improvise the therapeutic plus pharmacological properties of old cancer treatments. The efficacy and safety have advanced thoroughly owing to the supramolecular fabrication of the protein corona guard which acts as a targeting agent via managing the border between and biological systems and nanoparticles.